Vetr Inc. announced Merrimack Pharmaceuticals Inc (NASDAQ:MACK), bumping up its stock price target to $5.60 today
- Updated: November 27, 2016
In a report released on 11/28/2016 Vetr Inc. increased the stock price target of Merrimack Pharmaceuticals Inc (NASDAQ:MACK) to $5.60 reporting a possible downside of -0.13%.
Previously on Wednesday December 23, 2015, Mizuho Securities reported on Merrimack Pharmaceuticals Inc (NASDAQ:MACK) reduced the target price from $16.00 to $13.00. At the time, this indicated a possible upside of 0.71%.
Just yesterday Merrimack Pharmaceuticals Inc (NASDAQ:MACK) traded 2.23% higher at $6.42. Merrimack Pharmaceuticals Inc’s 50-day moving average is $5.59 and its 200-day moving average is $5.67. The last closing price is up 13.13% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.03% over the same time period. 0 shares of MACK traded hands, down from an average trading volume of 3,247,150
Recent Performance Chart
Merrimack Pharmaceuticals Inc has 52 week low of $4.39 and a 52 week high of $9.63 and has a market capitalization of $0.
Brief Synopsis On Merrimack Pharmaceuticals Inc (NASDAQ:MACK)
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. Its therapeutic oncology candidates in clinical development include MM-398, MM-302, MM-121, MM-141 and MM-151. Its ONIVYDE (irinotecan liposome injection), also known as MM-398, is an encapsulation of the marketed chemotherapy drug irinotecan in a liposomal formulation. MM-302 is an antibody drug conjugated liposomal doxorubicin that targets the ErbB2 (HER2) receptor. MM-121 is a fully human monoclonal antibody that targets Erb-B2 Receptor Tyrosine Kinase 3 (ErbB3). MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes. MM-151 is an oligoclonal therapeutic designed to bind to non-overlapping epitopes of EGFR (ErbB1).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.